Skip to main content
DNTH
NASDAQ Life Sciences

Dianthus CEO 及关键高管清仓所有直接持有的股票

feedReported by Wiseek News
Sentiment info
Negative
Importance info
8
Price
$77.8
Mkt Cap
$3.463B
52W Low
$13.365
52W High
$88.02
Market data snapshot near publication time

summarizeSummary

Dianthus Therapeutics 的 CEO 和总裁、首席会计官以及 EVP 和研发负责人于 2026 年 3 月 12 日集体出售了约 1634 万美元的普通股。值得注意的是，所有三位高管根据 Rule 10b5-1 交易计划出售了其在公司的全部直接持股。这一重大内部卖出事件发生在公司完成增大 4 亿美元公开募股之后不久。虽然这些交易是在预先安排的计划下执行的，但包括 CEO 在内的多位高管清仓直接持有的股票，可以被市场解读为他们对公司长期表现缺乏信心的负面信号，可能会影响投资者情绪。

在该公告发布时，DNTH的交易价格为$77.80，交易所为NASDAQ，所属行业为Life Sciences，市值约为$34.6亿。 52周交易区间为$13.37至$88.02。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Wiseek News。

show_chartPrice Chart

Share this article

Copied!

feed DNTH - Latest Insights

DNTH
Mar 26, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Dianthus Therapeutics Secures $676M in Offering, Receives Favorable FDA Feedback for Claseprubart Trials
Sentiment: Positive
View Wiseek Article
DNTH
Mar 13, 2026, 8:40 PM EDT
Source: Wiseek News
Importance Score:
8
Dianthus CEO, Key Executives Liquidate All Direct Stock Holdings
Sentiment: Negative
View Wiseek Article
DNTH
Mar 12, 2026, 7:20 AM EDT
Filing Type: 8-K
Importance Score:
8
Dianthus Therapeutics Finalizes $673.5M Upsized Public Offering, Including Full Underwriter Option Exercise
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 11, 2026, 5:28 PM EDT
Filing Type: 424B5
Importance Score:
8
Dianthus Therapeutics Prices $625M Public Offering at $81.00 Per Share, Extending Cash Runway
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 10, 2026, 10:56 PM EDT
Source: Reuters
Importance Score:
8
Dianthus Therapeutics Prices Upsized $625M Offering at $81/Share
Sentiment: Negative
View Wiseek Article
DNTH
Mar 10, 2026, 9:54 PM EDT
Filing Type: S-3MEF
Importance Score:
8
Dianthus Therapeutics Upsizes Shelf Registration by $120M, Increasing Capital Raise Capacity to $720M
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 09, 2026, 5:25 PM EDT
Filing Type: 424B5
Importance Score:
9
Dianthus Therapeutics Details Proposed $400M Public Offering Following Positive Phase 3 Trial Results
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dianthus Therapeutics Commences $400M Public Offering Following Positive Phase 3 Trial News
Sentiment: Negative
View Wiseek Article
DNTH
Mar 09, 2026, 7:21 AM EDT
Filing Type: 10-K
Importance Score:
9
Dianthus Therapeutics Reports Early Phase 3 Success for Claseprubart in CIDP, Extends Cash Runway
Sentiment: Positive
View Wiseek Article
DNTH
Mar 09, 2026, 7:19 AM EDT
Filing Type: 8-K
Importance Score:
9
Dianthus Therapeutics Achieves Early GO Decision in Pivotal Phase 3 CIDP Trial for Claseprubart
Sentiment: Positive
View Wiseek Article